Executive Summary

1
Executive Summary

• Platform Technology (TSCP)
• Fusion proteins with two functional ends
• First-in-class drugs to convert inter-cellular
  signals
• Studied for a decade / Multiple scientific
  publications
• Wide IP estate licensed from the University of
  Pennsylvania
• Products
• Pipeline Four TSCP fusion combinations
• Two products in pre-clinical development
• Autoimmune indications with unmet needs
• KAHR-101
• Complete production process developed
• Efficacy demonstrated in multiple animal disease
  models
• Clinical trials expected in 2010 in RA patients

2
Company Information

• Hadasit Bio-Holdings (HBL, TASE HDST)
  portfolio company
• Located in Israel
• Operations initiated mid 2007
• Platform technology Trans signal converter
  proteins (TSCP). Licensed from the University of
  Pennsylvania
• Leading products KAHR-101 KAHR-102 for the
  treatment of autoimmune diseases

3
Team

• CEO Dr. Noam Shani, Ph.D. Previous VP-RD for
  Medgenics (AIM MEDG) and for Compugen (NASDAQ
  CGEN)
• Research Officer - Dr. Michal Dranitzki Elhalel,
  M.D. Senior physician and scientist at the
  Hadassah Medical Center. Investigating the TSCP
  technology since 2000
• Scientific Advisory Board
• Prof. Marc Feldmann, M.D., Ph.D. Head, Kennedy
  Institute of Rheumatology - Imperial College,
  London. Developed Ramicade (JJ)
• Prof. Lawrence Steinman, M.D. Chair of Immunology
  at Stanford University. Developed Tysabri
  (Biogen-Idec)
• Dr. Nabil Hanna, Ph.D. Previous Executive Vice
  President Research, Biogen-Idec. Developed
  Rituximab and Zevalin (Biogen-Idec)
• Prof. Mark Tykocinski, M.D. Dean, Jefferson
  Medical College, Philadelphia. Inventor of the
  TSCP platform technology

4
Platform Technology TSCP

• Represents the third generation of protein-based
  therapeutics
• First generation Protein with one functional
  unit and one target (e.g. IFN, EPO, hGH)
• Second generation Protein with two functional
  units and one target (e.g. mAb, Fc-fusions)
• Third generation Protein with two functional
  units and two targets (TSCP molecules)
• Fusion proteins with Two functional ends
• Both sides transmit different and complementary
  intercellular or intracellular signals
• Intensely studied for a decade, mostly by U. Penn
  and Hadassah teams
• Drug potential documented in multiple scientific
  publications
• IP was licensed from U. Penn
• See website for scientific publications
  www.kahr-medical.com

5
KAHR-101/102 Three-Year Plan
6
KAHR Opportunity

• Technological breakthrough TSCP platform
  technology
• Huge market with unmet clinical needs
• Competitive advantage over existing paradigm
• Robust development pipeline
• Strong IP portfolio
• Seasoned team
• KAHR has initiated a series-A financing round and
  is seeking strategic investments, licensing and
  co-development collaborations